You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
|
|---|---|
| Published in |
Lancet Oncology, September 2016
|
| DOI | 10.1016/s1470-2045(16)30364-3 |
| Pubmed ID | |
| Authors |
Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P D'Angelo, Kent C Shih, Céleste Lebbé, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D Lewis, Jochen H Lorch, Kevin Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 38% |
| United Kingdom | 4 | 19% |
| Turkey | 1 | 5% |
| France | 1 | 5% |
| Venezuela, Bolivarian Republic of | 1 | 5% |
| Unknown | 6 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 57% |
| Practitioners (doctors, other healthcare professionals) | 5 | 24% |
| Scientists | 3 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 592 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | <1% |
| France | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 589 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 75 | 13% |
| Student > Bachelor | 66 | 11% |
| Other | 64 | 11% |
| Student > Ph. D. Student | 58 | 10% |
| Student > Master | 48 | 8% |
| Other | 111 | 19% |
| Unknown | 170 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 215 | 36% |
| Biochemistry, Genetics and Molecular Biology | 63 | 11% |
| Agricultural and Biological Sciences | 33 | 6% |
| Immunology and Microbiology | 19 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 3% |
| Other | 55 | 9% |
| Unknown | 188 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 71. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2023.
All research outputs
#610,241
of 26,017,215 outputs
Outputs from Lancet Oncology
#773
of 6,958 outputs
Outputs of similar age
#11,702
of 353,959 outputs
Outputs of similar age from Lancet Oncology
#11
of 132 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,959 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.